View Post

55,000 Sudan Ebolavirus Vaccine Candidates Coming by Year End

In COVID-19, Latest News by Precision Vaccinations

The nonprofit scientific research organization IAVI and Merck & Co., Inc. announced today they have entered into an agreement that could enable IAVI to accelerate the entry of a Sudan ebolavirus (SUDV) vaccine candidate that could be deployed in the Republic of Uganda this year.
The Ministry of Health of Uganda has declared a SUDV outbreak in several districts that have claimed about 28 lives since late September 2022.

View Post

Herpes Virus Sheds for Several Months

In COVID-19, Latest News by Precision Vaccinations

An Original Investigation reported concerning news for people recently diagnosed with genital herpes simplex virus type 1 (HSV-1).
The peer-review journal The JAMA Network found genital HSV-1 shedding was frequent after the first episode, particularly among individuals with primary infection.
However, HSV-1 shedding declined rapidly during the first year following infection.
Whether the decline in genital HSV-1 shedding over time is due to virologic or immunologic factors was unclear, wrote these researchers.

View Post

London's Poliovirus Confirmations Continue Unabated

In COVID-19, Latest News by Precision Vaccinations

The U.K. Health Security Agency (UKHSA) recently announced it continues investigating the source of the poliovirus identified in wastewater systems across London, England.
The UKHSA stated on October 19, 2022, it is most likely that an individual entered the U.K. in February 2022 from a country where the oral polio vaccine (OPV) had been used for immunization campaigns. 
Recently vaccinated individuals can shed the OPV virus in their stool for a few weeks following vaccination enabling the virus to be detected through sewage surveillance.

View Post

Flu Shots Flopped Last Season

In COVID-19, Latest News by Precision Vaccinations

During the two-day U.S. CDC Advisory Committee on Immunization Practices (ACIP) meeting led by Dr. Grace Lee, several presentations revealed significant vaccine progress and measurable health impact.
However, when Jessie Chung MPH, Samantha Olson MPH, and Nathaniel Lewis Ph.D. presented the preliminary influenza vaccine efficacy (VE) results from the last flu season, various ACIP members expressed shock and dismay.